References:
1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 24 February 2014.
2. Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 2014;10(4):561-580.
3. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441-1458.
4. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36(12):1585-1592.
5. von Hentig N, Haberl A. Safety of pharmacoenhancers for HIV therapy. Expert Rev Clin Pharmacol. 2012;5(5):557-568.
6. AbbVie Inc. Prescribing information for Norvir® (Ritonavir). 2013; http://www.rxabbvie.com/pdf/norvirtab_pi.pdf. Accessed 23 February 2015
7. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 2007;51(10):3617-3626
8. Sara BD Olalla M, Ana LP, et al. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study Pharmacotherapy 2020;40(1):17–25
9. Li Zhu, Roger J Brüggemann, Jonathan Uy et al., CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.J Clin Pharmacol. 2017 Feb;57(2):235-246
10. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am 2016;62(4):e1-50.
11. Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am 2016;63(4):e1-60.
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15.
13. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21(3):240-8.
14. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triaole antifungal agent voriconazole. Pharmacogenomics 2011;12(6):861-72.
15. Brad Moriyama1, Oluwaseun Falade, Janice Leung et al., Prolonged Half-life of Voriconazole in a CYP2C19 Homozygous Poor Metabolizer Receiving Vincristine Chemotherapy: Avoiding a Serious Adverse Drug Interaction Mycoses. 2011 November ; 54(6): e877-e879.
16. Andreas HG, Robert T, Amit D et al., Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017 Oct;19(5):1-11.
17. Whitley MY, Kelly ES, Jaclyn J et al., Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017; 16: 60.
18. Mette Marie Hougaard Christensen, Maija Bruun Haastrup, Thomas Øhlenschlæger et al,, Interaction potential between clarithromycin and individual statins—A systematic review. Basic Clin Pharmacol Toxicol. 2020;126:307–317.